ArticlePloS one2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.
Open access · goldAbstract read
In one paragraph
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 71 citations in OpenAlex.
- Quantifying how HIV-1 envelope sequence features impact vaccine efficacy in the HVTN 705/HPX2008 randomised trial in southern African women.EBioMedicine · 2026Trial
- Trial
- Candidate correlates of protection in the HVTN505 HIV-1 vaccine efficacy trial identified by positive-unlabeled learning.PLoS computational biology · 2025Trial
- Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.Vaccine · 2021Trial
- Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand.PLoS pathogens · 2020Trial
- Cross-Reactive CD8 T-Cell Responses Elicited by Adenovirus Type 5-Based HIV-1 Vaccines Contributed to Early Viral Evolution in Vaccine Recipients Who Became Infected.Journal of virology · 2020Trial
- Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.The Journal of clinical investigation · 2019Trial
- Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.The Journal of infectious diseases · 2018Trial
- Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection.Nature communications · 2026Article
- Article
- Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants.Science advances · 2025Article
- Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV Infection.bioRxiv : the preprint server for biology · 2025Article
- Candidate Correlates of Protection in the HVTN505 HIV-1 Vaccine Efficacy Trial Identified by Positive-Unlabeled Learning.medRxiv : the preprint server for health sciences · 2025Article
- Progress and Recent Developments in HIV Vaccine Research.Vaccines · 2025Review
- Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research.iScience · 2023Article
- Nonparametric estimation of marked survival data in the presence of dependent censoring.Statistics in medicine · 2023Article
- Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.Nature reviews. Immunology · 2023Review
- Review
- Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection.Virus evolution · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 8 institutions in 2 countries.
Allan C deCampVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.ORCID http://orcid.org/0000-0003-1404-4322
Morgane RollandUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Paul T EdlefsenVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Eric Sanders-BuellUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Breana HallDepartment of Microbiology, University of Washington, Seattle, Washington, United States of America.
Craig A MagaretVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Andrew J Fiore-GartlandVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Michal JuraskaVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Lindsay N CarppVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Shelly T KarunaVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Meera BoseUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Steven LePoreUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Shana MillerUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Annemarie O'SullivanUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Kultida PoltaveeUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Hongjun BaiUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Kalpana DommarajuUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Hong ZhaoDepartment of Microbiology, University of Washington, Seattle, Washington, United States of America.
Kim WongDepartment of Microbiology, University of Washington, Seattle, Washington, United States of America.
Lennie ChenDepartment of Microbiology, University of Washington, Seattle, Washington, United States of America.
Hasan AhmedDepartment of Biology, Emory University, Atlanta, Georgia, United States of America.
Derrick GoodmanDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Matthew Z TayDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Raphael GottardoVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Richard A KoupVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Robert BailerVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Robert J O'ConnellUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Nelson L MichaelUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Merlin L RobbUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Elizabeth AdamsThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
Patricia D'SouzaDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
James KublinVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Lawrence CoreyVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Daniel E GeraghtyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Nicole FrahmVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Georgia D TomarasDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
M Juliana McElrathVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Lisa FrenkelDepartment of Global Health, University of Washington, Seattle, Washington, United States of America.
Sheila StyrchakSeattle Children's Research Institute, Seattle, Washington, United States of America.
Sodsai TovanabutraUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Magdalena E SobieszczykDepartment of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, United States of America.
Scott M HammerDepartment of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, United States of America.
Jerome H KimInternational Vaccine Institute, Seoul, Korea.
James I MullinsDepartment of Microbiology, University of Washington, Seattle, Washington, United States of America.
Peter B GilbertVaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Henry M. Jackson Foundation · USUniversity of Washington · USFred Hutch Cancer Center · USNational Institutes of Health · USDuke University · USColumbia University Irving Medical Center · USEmory University · USInternational Vaccine Institute · KR
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MLC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MStatistical Methods in HIV Vaccine Efficacy TrialsR37AI054165 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert · 2010 to 2026
$6.7MNIAID NIH HHS R37 AI054165NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635
Abstract
Although the HVTN 505 DNA/recombinant adenovirus type 5 vector HIV-1 vaccine trial showed no overall efficacy, analysis of breakthrough HIV-1 sequences in participants can help determine whether vaccine-induced immune responses impacted viruses that caused infection. We analyzed 480 HIV-1 genomes sampled from 27 vaccine and 20 placebo recipients and found that intra-host HIV-1 diversity was significantly lower in vaccine recipients (P ≤ 0.04, Q-values ≤ 0.09) in Gag, Pol, Vif and envelope glycoprotein gp120 (Env-gp120). Furthermore, Env-gp120 sequences from vaccine recipients were significantly more distant from the subtype B vaccine insert than sequences from placebo recipients (P = 0.01, Q-value = 0.12). These vaccine effects were associated with signatures mapping to CD4 binding site and CD4-induced monoclonal antibody footprints. These results suggest either (i) no vaccine efficacy to block acquisition of any viral genotype but vaccine-accelerated Env evolution post-acquisition; or (ii) vaccine efficacy against HIV-1s with Env sequences closest to the vaccine insert combined with increased acquisition due to other factors, potentially including the vaccine vector.
Indexed as
AdolescentAdultAIDS VaccinesBinding SitesCD4 AntigensFemaleHIV-1HIV Envelope Protein gp120HumansMaleMiddle AgedYoung AdultAIDS VaccinesCD4 AntigensHIV Envelope Protein gp120
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.